Quarterly report pursuant to Section 13 or 15(d)

Licensing and Other Arrangements - ObsEva (Details)

v3.23.1
Licensing and Other Arrangements - ObsEva (Details) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Nov. 21, 2022
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Asset acquisition        
Estimated useful life of intangible asset 17 years      
Amortization expense   $ 225    
Revenue recognized     $ 2,750  
License Agreement | Organon        
Asset acquisition        
Maximum eligible milestone payments receivable upon achievement of development, commercialization and sales-based milestones $ 475,000      
ObsEva IP        
Asset acquisition        
Upfront cash payment to acquire assets 15,000      
Cost to acquire assets 15,200      
Transaction costs $ 200      
Estimated useful life of intangible asset 17 years      
Amortization expense   200    
Impairment of intangible asset   0   $ 0
ObsEva IP | License Agreement        
Asset acquisition        
Maximum earn-out payments $ 97,500      
Maximum earn-out payments for development and regulatory milestones 46,500      
Maximum earn-out payments for sales-based milestones $ 51,000      
Contract assets   0   0
Contract liabilities   0   $ 0
Revenue recognized   $ 0